GlassScriptPhysician profile
William Curry Mcevoy
NPI 1821222761
$19,971.34
in general payments reported to CMS, 2019-2025
82 companies · $3,153 in 2025
The $3,153 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,749 · 2020: $1,884 · 2021: $2,925 · 2022: $2,919 · 2023: $3,156 · 2024: $3,187 · 2025: $3,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,242 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,242.20 |
| Education | $252.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,100.59 | 2019-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $1,440.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,170.68 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Genentech USA, INC. | $1,124.33 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $1,079.05 | 2019-2025 | Opdivo |
| Incyte Corporation | $1,018.66 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $945.42 | 2019-2025 | Erleada, Balversa, Rybrevant |
| Amgen INC. | $831.05 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Celgene Corporation | $769.45 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Astellas Pharma US INC | $713.09 | 2019-2025 | Xtandi, Xospata, Padcev |
| Eisai INC. | $638.75 | 2019-2025 | |
| Pfizer INC. | $507.07 | 2019-2025 | |
| Daiichi Sankyo INC. | $503.14 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Regeneron Healthcare Solutions, INC. | $476.87 | 2022-2025 | Libtayo, Lynozyfic |
| Lilly USA, LLC | $456.07 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcevoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.